Artelo Biosciences, Inc. (ARTL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Artelo Biosciences reported revenue of $0. Net income was -$12.9M, or -$338.04 per diluted share. Operating activities generated -$8.5M of cash. At fiscal year end, Artelo Biosciences held $2.8M in total assets against $4.1M in total liabilities, including $600,000 of cash and equivalents.
Open the full interactive Artelo Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Artelo Biosciences Key Stats
| Share Price | $2.98 |
|---|---|
| Market Cap | $897,973 |
| 52-Week Range | $2.98 – $113.40 |
| Shares Outstanding | 18.7 million (basic, 2021 Q4) |
Artelo Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$4.7M | -$7.4M | -$10.3M | -$9.9M | -$10.1M | -$11.4M |
| Pre-Tax Income | -$4.7M | -$7.4M | -$10.1M | -$9.3M | -$9.8M | -$12.9M |
| Income Tax | $0 | — | $0 | $0 | $0 | $0 |
| Net Income | -$4.7M | -$7.4M | -$10.1M | -$9.3M | -$9.8M | -$12.9M |
| Diluted EPS | -$3061.80 | -$972.00 | — | — | -$494.10 | -$338.04 |
Artelo Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.1M | -$4.2M | -$3.0M | -$2.4M |
| Diluted EPS | -$107.19 | -$4.05 | -$36.00 | -$8.01 |
Artelo Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $6.6M | $6.9M | — | — | $600,000 |
| Current Assets | $2.3M | $10.3M | $18.3M | $11.0M | $2.6M | $695,000 |
| Total Assets | $4.4M | $12.6M | $20.4M | $13.0M | $4.7M | $2.8M |
| Current Liabilities | $502,177 | $526,000 | $998,000 | $1.3M | $1.8M | $4.0M |
| Total Liabilities | $502,177 | $593,000 | $1.0M | $1.3M | $1.8M | $4.1M |
| Shareholders' Equity | $3.9M | $12.0M | $19.4M | $11.8M | $2.9M | -$1.3M |
Artelo Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.3M | -$6.1M | -$8.0M | -$8.2M | -$8.3M | -$8.5M |
| Cash From Investing | $84,753 | -$3.4M | $3.0M | $3.5M | $7.8M | -$62,000 |
| Cash From Financing | $2.0M | $14.1M | $0 | $567,000 | $112,000 | $6.9M |
Figures from Artelo Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Artelo Biosciences financials page for every line item.
Artelo Biosciences Company Profile
| Ticker | ARTL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Solana Beach, California |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001621221 |
Frequently Asked Questions
What was Artelo Biosciences' revenue in fiscal 2025?
Artelo Biosciences (ARTL) reported revenue of $0 for fiscal 2025.
What is Artelo Biosciences' annual revenue history?
Artelo Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Artelo Biosciences' net income in fiscal 2025?
Artelo Biosciences reported net income of -$12.9M for fiscal 2025.
What was Artelo Biosciences' earnings per share (EPS) in fiscal 2025?
Artelo Biosciences' diluted EPS was -$338.04 for fiscal 2025 (adjusted for any later stock splits).
What was Artelo Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Artelo Biosciences reported revenue of $0.
How many shares of Artelo Biosciences are outstanding?
Artelo Biosciences reported a weighted average of 18.7 million basic shares outstanding in 2021 Q4.
What is Artelo Biosciences' market cap?
Based on its latest closing price, Artelo Biosciences (ARTL) has a market capitalization of about $897,973.
When does Artelo Biosciences' fiscal year end?
Artelo Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Artelo Biosciences headquartered?
Artelo Biosciences lists its business address in Solana Beach, California in its SEC filings.